FDA v. R. J. Reynolds Vapor Co.
The Supreme Court ruled 7–2 that e-cigarette retailers can join manufacturers in challenging the FDA's rejection of a new tobacco product application, holding that retailers are among the people the law allows to sue.
The ruling has immediate practical consequences for where such cases can be filed: retailers can bring their challenge in any federal circuit where they are located, potentially giving manufacturers access to courts they could not reach on their own.
How it got here: The FDA denied RJR Vapor's application; RJR Vapor and retailers filed a joint challenge in the Fifth Circuit; the Fifth Circuit denied the FDA's motion to dismiss or transfer; the FDA asked the Supreme Court to review that ruling.
The Case in Depth
What happened
R.J. Reynolds Vapor Company makes e-cigarettes, including the popular Vuse Alto line. After the FDA denied its applications to market flavored Vuse Alto products, RJR Vapor did not file alone. Instead, it teamed up with a Texas-based retailer and a Mississippi convenience-store trade association — filing a joint legal challenge in the Fifth Circuit, where those retailers are located. Had RJR Vapor filed alone, it could only have sued in the D.C. Circuit or the Fourth Circuit, which covers North Carolina, RJR Vapor's home state.
The question before the Court
Can e-cigarette retailers — who play no role in the FDA approval process — sue in court to challenge the FDA's rejection of a manufacturer's application to sell a new tobacco product?
The Court's answer
Yes — retailers who sell (or hoped to sell) a product that the FDA has rejected can challenge that rejection in court. The Tobacco Control Act allows "any person adversely affected" by an FDA denial order to seek judicial review. The Court held that retailers qualify: when the FDA rejects an application, retailers lose the opportunity to profit from selling the product and face criminal penalties if they stock it anyway. Their interests are directly tied to the statute's subject matter, putting them well within the law's protection.
The FDA had argued that only the manufacturer who applied for approval is genuinely "adversely affected." The Court rejected this, pointing to a telling contrast inside the statute itself. Congress used the broad phrase "any person adversely affected" for denial orders, but used the narrow phrase "holder of the application" when it limited who can challenge withdrawal of an already-approved product. That internal distinction shows Congress knew how to be specific when it wanted to — and deliberately chose broader language in the denial-order review provision.
Curious how the Court got there? See the step-by-step legal reasoning →
Why it matters
Tobacco and e-cigarette retailers now have an independent legal right to challenge FDA decisions rejecting new product applications. In practice, this also expands the pool of federal courts available for such challenges — a retailer's home circuit becomes a valid venue, which manufacturers can use strategically to steer cases away from courts that have already ruled against them on similar applications.
What changes now
The case returns to the Fifth Circuit, which will now decide whether the FDA acted lawfully in rejecting RJR Vapor's Vuse Alto applications on the merits. Today's ruling resolves only who may sue and where — not whether the FDA's rejection was correct. A separate unresolved question — whether each co-petitioner in a joint petition must independently qualify to file in a given circuit — was not decided and remains open for future litigation.
What this does not decide
The Court did not decide whether every petitioner in a joint review petition must independently satisfy the statute's venue requirements — a question the FDA raised for the first time before the Supreme Court. The Court also did not reach whether the FDA properly rejected the Vuse Alto applications on the merits.
Concurrences and dissents
Dissent — Justice Jackson
“No matter how long you stare at §387j, you will not find anything looking out for retailers. They are simply not protected by the provision at all.”The dissent argues retailers are entirely absent from the statutory scheme governing the FDA's premarket approval process.
Justice Jackson argues the majority applies the zone-of-interests test incorrectly by focusing on the broad language of the judicial-review provision rather than on the specific provision the FDA allegedly violated — the premarket-approval scheme in §387j. Analyzed properly, that scheme is an exclusive two-party arrangement between manufacturers and the FDA; retailers have no procedural rights, receive no notices, and play no role whatsoever. The dissent also argues the ruling allows manufacturers like RJR Vapor to evade the statute's venue restrictions by teaming up with retailers located in more favorable circuits.
How the Court got there
The legal reasoning, step by step
- The Tobacco Control Act authorizes 'any person adversely affected' by an FDA denial of a new tobacco product application to seek court review. The Court applied the 'zone of interests' test — a framework used to determine whether a particular person belongs to the class Congress meant to allow to sue — asking whether retailers' interests are 'arguably within the zone of interests' the statute protects.
- The Court established that 'adversely affected' is a legal term of art with a long, consistent history across federal statutes. Most importantly, the phrase appears in the Administrative Procedure Act (APA), the main federal law governing court review of agency decisions, where it has long been read broadly. The Court has applied that same broad reading when interpreting similar phrases in other statutes, including the Fair Housing Act, Title VII, and the Longshore and Harbor Workers' Compensation Act.
- The FDA argued the broad reading of 'adversely affected' is unique to the APA, and that for specific statutes like the Tobacco Control Act, only the person with the closest relationship to the denial — the applicant manufacturer — qualifies. The Court rejected this distinction: in each of the non-APA cases cited, the Court borrowed the APA's broad 'zone of interests' framework without confining it to APA suits.
- Retailers satisfy the standard. If the FDA rejects an application, retailers lose sales revenue from the product — and risk criminal penalties if they sell it anyway without authorization. Their interests are not 'so marginally related to or inconsistent with' the statute's purposes that Congress should be presumed to have meant to exclude them.
- The Court also pointed to a revealing textual contrast within the Tobacco Control Act itself. When Congress wanted to limit who could challenge the FDA's withdrawal of an already-approved product, it said only the 'holder of the application' could sue. For denial orders, Congress used the broader 'any person adversely affected.' Using materially different terms in the same statute creates a strong presumption that different things are meant — and fatally undermines the FDA's argument that the two provisions should be read the same way.
- A third argument — that every petitioner in a joint petition must independently establish the right to file in a given court — was raised by the FDA for the first time at the Supreme Court and had not been analyzed by the Fifth Circuit. The Court declined to address it, noting that prudence counsels waiting for a case where the issue has been fully developed in the lower courts, especially because any ruling on that question would affect similar venue statutes across federal law.
Doctrinal impact
Cases affected by this decision
Distinguishes Block v. Community Nutrition Institute (467 U.S. 340)
The majority says Block's consumer-exclusion logic does not apply here because the Tobacco Control Act has only one cause of action and no administrative exhaustion requirement.
Reaffirms Thompson v. North American Stainless, LP (562 U.S. 170)
Reaffirmed as precedent for reading 'person aggrieved' broadly across statutes, not just under the APA.